Yuyu Pharma유유제약
000220 · KOSPI · ₩000220 · 유유제약
₩3,650▼ ₩40 (1.08%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩141B | ₩133B | ₩137B | ₩139B | ₩116B |
| Cost of sales | ₩87B | ₩81B | ₩88B | ₩86B | ₩70B |
| Gross profit | ₩54B | ₩52B | ₩49B | ₩53B | ₩45B |
| Operating income | ₩11B | ₩12B | ₩365M | −₩592M | ₩1.2B |
| Net income | ₩9.1B | ₩10B | −₩5.5B | −₩4.4B | −₩920M |
| Net income to shareholders | ₩8.2B | ₩8.7B | −₩7.2B | −₩6B | −₩2.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩207B | ₩208B | ₩198B | ₩195B | ₩193B |
| Current assets | ₩97B | ₩102B | ₩102B | ₩96B | ₩99B |
| Cash and equivalents | ₩29B | ₩42B | ₩31B | ₩26B | ₩50B |
| Total liabilities | ₩67B | ₩73B | ₩78B | ₩72B | ₩64B |
| Current liabilities | ₩59B | ₩64B | ₩50B | ₩64B | ₩30B |
| Total equity | ₩141B | ₩135B | ₩120B | ₩123B | ₩129B |
| Shareholders' equity | ₩130B | ₩125B | ₩112B | ₩117B | ₩124B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩16B | ₩25B | ₩421M | −₩6.2B | ₩4.5B |
| Capital spending | ₩8.3B | ₩7.1B | ₩4.5B | ₩5.3B | ₩6.1B |
| Free cash flow | ₩7.6B | ₩18B | −₩4.1B | −₩12B | −₩1.6B |
| Dividends paid | ₩1.9B | — | ₩2B | ₩2B | ₩1.9B |
Consolidated where available. Amounts in won.
Also known as: Yuyu Pharma / 유유제약 / 000220 / KRX:000220
Source: KRX statistical information